Endocrinology, Vol 136, 660-667, Copyright © 1995 by Endocrine Society

ARTICLES

Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice

NY Chen, WY Chen, L Bellush, CW Yang, LJ Striker, GE Striker and JJ Kopchick
Department of Biological Sciences, Ohio University, Athens 45701.

To investigate GH's role in diabetic end organ damage, experimental diabetes was induced with streptozotocin (STZ) in bovine GH (bGH) or bGH antagonist transgenic mice and in their nontransgenic (NTG) litter mates. Body growth, blood glucose, serum insulin-like growth factor-I levels, liver GH receptor (GHR) binding, and kidney histology of these animals were evaluated. After administration of multiple low doses of STZ, 90% of the mice developed hyperglycemia. The diabetic animals, especially those expressing GH and GH antagonist transgenes, demonstrated retarded body growth and reduced insulin-like growth factor-I levels when compared with their nondiabetic litter mates. Kidney histology revealed severe glomerulosclerosis in diabetic and nondiabetic bGH transgenic mice. Diabetic NTG mice exhibited moderate kidney lesions. Diabetic bGH antagonist transgenic mice possessed normal glomeruli indistinguishable from those seen in nondiabetic NTG mice. GHR-binding assays revealed that liver GHR-binding sites were significantly reduced in diabetic NTG mice and transgenic dwarf mice when compared with their nondiabetic controls. Conversely, liver GHR- binding ability was significantly increased in bGH transgenic mice as compared with their NTG littermates and remained high during diabetes. It is concluded that transgenic mice that express a GH antagonist are protected from diabetes and or GH-induced nephropathy.

This article has been cited by other articles:

				G. R. Reddy, M. J. Pushpanathan, R. F. Ransom, L. B. Holzman, F. C. Brosius III, M. Diakonova, P. Mathieson, M. A. Saleem, E. O. List, J. J. Kopchick, et al. Identification of the Glomerular Podocyte as a Target for Growth Hormone Action Endocrinology, May 1, 2007; 148(5): 2045 - 2055. [Abstract] [Full Text] [PDF]

				Y. Zha, V. T. Le, Y. Higami, I. Shimokawa, T. Taguchi, and M. S. Razzaque Life-Long Suppression of Growth Hormone-Insulin-Like Growth Factor I Activity in Genetically Altered Rats Could Prevent Age-Related Renal Damage Endocrinology, December 1, 2006; 147(12): 5690 - 5698. [Abstract] [Full Text] [PDF]

				A. Fornoni, S. A. Rosenzweig, O. Lenz, A. Rivera, G. E. Striker, and S. J. Elliot Low Insulin-Like Growth Factor Binding Protein-2 Expression Is Responsible for Increased Insulin Receptor Substrate-1 Phosphorylation in Mesangial Cells from Mice Susceptible to Glomerulosclerosis Endocrinology, July 1, 2006; 147(7): 3547 - 3554. [Abstract] [Full Text] [PDF]

				D. E. Berryman, E. O. List, D. T. Kohn, K. T. Coschigano, R. J. Seeley, and J. J. Kopchick Effect of Growth Hormone on Susceptibility to Diet-Induced Obesity Endocrinology, June 1, 2006; 147(6): 2801 - 2808. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF]

				A. F. Muller, J. J. Kopchick, A. Flyvbjerg, and A. J. van der Lely Growth Hormone Receptor Antagonists J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1503 - 1511. [Full Text] [PDF]

				S. Mizuno and T. Nakamura Suppressions of chronic glomerular injuries and TGF-{beta}1 production by HGF in attenuation of murine diabetic nephropathy Am J Physiol Renal Physiol, January 1, 2004; 286(1): F134 - F143. [Abstract] [Full Text] [PDF]

				K. T. Coschigano, A. N. Holland, M. E. Riders, E. O. List, A. Flyvbjerg, and J. J. Kopchick Deletion, But Not Antagonism, of the Mouse Growth Hormone Receptor Results in Severely Decreased Body Weights, Insulin, and Insulin-Like Growth Factor I Levels and Increased Life Span Endocrinology, September 1, 2003; 144(9): 3799 - 3810. [Abstract] [Full Text] [PDF]

				R. M. Mason and N. A. Wahab Extracellular Matrix Metabolism in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373. [Abstract] [Full Text] [PDF]

				J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly Endocr. Rev., October 1, 2002; 23(5): 623 - 646. [Abstract] [Full Text] [PDF]

				T. O'Connell and D. R. Clemmons IGF-I/IGF-Binding Protein-3 Combination Improves Insulin Resistance By GH-Dependent and Independent Mechanisms J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4356 - 4360. [Abstract] [Full Text] [PDF]

				A. C.P. Thirone, J. A. Scarlett, A. L. Gasparetti, E. P. Araujo, M. H.L. Lima, C. R.O. Carvalho, L. A. Velloso, and M. J.A. Saad Modulation of Growth Hormone Signal Transduction in Kidneys of Streptozotocin-Induced Diabetic Animals: Effect of a Growth Hormone Receptor Antagonist Diabetes, July 1, 2002; 51(7): 2270 - 2281. [Abstract] [Full Text] [PDF]

				V. ROELFSEMA and R. G. CLARK The Growth Hormone and Insulin-Like Growth Factor Axis: Its Manipulation for the Benefit of Growth Disorders in Renal Failure J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1297 - 1306. [Abstract] [Full Text]

				S. Q. DOI, T. A. JACOT, D. F. SELLITTI, P. HIRSZEL, M. H. HIRATA, G. E. STRIKER, and L. J. STRIKER Growth Hormone Increases Inducible Nitric Oxide Synthase Expression in Mesangial Cells J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1419 - 1425. [Abstract] [Full Text]

				K. T. Coschigano, D. Clemmons, L. L. Bellush, and J. J. Kopchick Assessment of Growth Parameters and Life Span of GHR/BP Gene-Disrupted Mice Endocrinology, July 1, 2000; 141(7): 2608 - 2613. [Abstract] [Full Text] [PDF]

				L. L. Bellush, S. Doublier, A. N. Holland, L. J. Striker, G. E. Striker, and J. J. Kopchick Protection against Diabetes-Induced Nephropathy in Growth Hormone Receptor/Binding Protein Gene-Disrupted Mice Endocrinology, January 1, 2000; 141(1): 163 - 168. [Abstract] [Full Text] [PDF]

				Y. SEGEV, D. LANDAU, R. RASCH, A. FLYVBJERG, and M. PHILLIP Growth Hormone Receptor Antagonism Prevents Early Renal in Nonobese Diabetic Mice J. Am. Soc. Nephrol., November 1, 1999; 10(11): 2374 - 2381. [Abstract] [Full Text]

				C. Costa, G. Solanes, J. Visa, and F. Bosch Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus FASEB J, November 1, 1998; 12(14): 1455 - 1460. [Abstract] [Full Text]

				Y. Wei, J. Li, W. Y. Chen, and T. E. Wagner Human Growth Hormone Antagonist (G120R) Delivered by a Murine Yolk Sac Cell-Derived Mini-Organ Decreases the Growth Rate of Mice Stem Cells, September 1, 1997; 15(5): 364 - 367. [Abstract] [Full Text]

				N.-y. Chen, W. Y. Chen, and J. J. Kopchick Liver and Kidney Growth Hormone (GH) Receptors Are Regulated Differently in Diabetic GH and GH Antagonist Transgenic Mice Endocrinology, May 1, 1997; 138(5): 1988 - 1994. [Abstract] [Full Text] [PDF]